Market Research Logo

Anthrax - Pipeline Review, H2 2015

Anthrax - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Anthrax - Pipeline Review, H2 2015’, provides an overview of the Anthrax’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Anthrax
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Anthrax and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Anthrax products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Anthrax pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Anthrax
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Anthrax Overview
Therapeutics Development
Pipeline Products for Anthrax - Overview
Pipeline Products for Anthrax - Comparative Analysis
Anthrax - Therapeutics under Development by Companies
Anthrax - Therapeutics under Investigation by Universities/Institutes
Anthrax - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Anthrax - Products under Development by Companies
Anthrax - Products under Investigation by Universities/Institutes
Anthrax - Companies Involved in Therapeutics Development
Aduro BioTech, Inc.
Altimmune, Inc.
Aphios Corporation
Aradigm Corporation
Bavarian Nordic A/S
Bristol-Myers Squibb Company
Cellceutix Corporation
ContraFect Corporation
Dynavax Technologies Corporation
Elusys Therapeutics, Inc.
Emergent BioSolutions Inc.
Green Cross Corporation
Grifols, S.A.
Hawaii Biotech, Inc.
iBio, Inc.
Innovative Biologics, Inc.
Microbiotix, Inc.
NanoBio Corporation
Oragenics, Inc.
PaxVax
Pfenex Inc.
PharmAthene, Inc.
Protein Potential, LLC
ProThera Biologics, LLC.
PsiOxus Therapeutics Limited
Soligenix, Inc.
Syntiron LLC
Tetraphase Pharmaceuticals Inc.
United Therapeutics Corporation
VLP Biotech, Inc.
Anthrax - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
anthrax + plague vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine - Drug Profile
anthrax vaccine next generation - Drug Profile
anthrax virus like particle vaccine - Drug Profile
ARD-3100 - Drug Profile
AV-7909 - Drug Profile
CF-306 - Drug Profile
CF-307 - Drug Profile
CF-308 - Drug Profile
ciprofloxacin hydrochloride - Drug Profile
DPX-Anthrax - Drug Profile
DV-230 - Drug Profile
Epimerox - Drug Profile
GC-1109 - Drug Profile
GREANX - Drug Profile
Human Antibody Based Vaccines - Drug Profile
KKL-35 - Drug Profile
Marinus - Drug Profile
MDX-1303 - Drug Profile
Monoclonal Antibody for Respiratory Anthrax - Drug Profile
Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile
MU-1140 - Drug Profile
MVA-BN Anthrax - Drug Profile
obiltoxaximab - Drug Profile
PBI-220 - Drug Profile
Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile
PMX-0196 - Drug Profile
PMX-0231 - Drug Profile
PMX-0243 - Drug Profile
PMX-225 - Drug Profile
PreviThrax - Drug Profile
Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile
Px-563L - Drug Profile
RC-100b - Drug Profile
RiVax + SGX-204 - Drug Profile
Second Generation Px-563L - Drug Profile
SGX-204 - Drug Profile
Small Molecule to Inhibit Anthrax Toxin and Alpha Hemolysin for Anthrax and Staphylococcal aureus Pneumonia - Drug Profile
Small Molecule to Inhibit DNA Helicase for Infectious Diseases - Drug Profile
Small Molecule to Inhibit Enoyl-Reductase for Bacillus Anthracis and Francisella Tularensis Infections - Drug Profile
Small Molecules for Bacterial Infections - Drug Profile
Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax - Drug Profile
Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile
Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile
Synthetic Peptides for Bacterial Infections - Drug Profile
TP-271 - Drug Profile
Anthrax - Recent Pipeline Updates
Anthrax - Dormant Projects
Anthrax - Discontinued Products
Anthrax - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Anthrax, H2 2015
Number of Products under Development for Anthrax - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015
Anthrax - Pipeline by Aduro BioTech, Inc., H2 2015
Anthrax - Pipeline by Altimmune, Inc., H2 2015
Anthrax - Pipeline by Aphios Corporation, H2 2015
Anthrax - Pipeline by Aradigm Corporation, H2 2015
Anthrax - Pipeline by Bavarian Nordic A/S, H2 2015
Anthrax - Pipeline by Bristol-Myers Squibb Company, H2 2015
Anthrax - Pipeline by Cellceutix Corporation, H2 2015
Anthrax - Pipeline by ContraFect Corporation, H2 2015
Anthrax - Pipeline by Dynavax Technologies Corporation, H2 2015
Anthrax - Pipeline by Elusys Therapeutics, Inc., H2 2015
Anthrax - Pipeline by Emergent BioSolutions Inc., H2 2015
Anthrax - Pipeline by Green Cross Corporation, H2 2015
Anthrax - Pipeline by Grifols, S.A., H2 2015
Anthrax - Pipeline by Hawaii Biotech, Inc., H2 2015
Anthrax - Pipeline by iBio, Inc., H2 2015
Anthrax - Pipeline by Innovative Biologics, Inc., H2 2015
Anthrax - Pipeline by Microbiotix, Inc., H2 2015
Anthrax - Pipeline by NanoBio Corporation, H2 2015
Anthrax - Pipeline by Oragenics, Inc., H2 2015
Anthrax - Pipeline by PaxVax, H2 2015
Anthrax - Pipeline by Pfenex Inc., H2 2015
Anthrax - Pipeline by PharmAthene, Inc., H2 2015
Anthrax - Pipeline by Protein Potential, LLC, H2 2015
Anthrax - Pipeline by ProThera Biologics, LLC., H2 2015
Anthrax - Pipeline by PsiOxus Therapeutics Limited, H2 2015
Anthrax - Pipeline by Soligenix, Inc., H2 2015
Anthrax - Pipeline by Syntiron LLC, H2 2015
Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2015
Anthrax - Pipeline by United Therapeutics Corporation, H2 2015
Anthrax - Pipeline by VLP Biotech, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Anthrax Therapeutics - Recent Pipeline Updates, H2 2015
Anthrax - Dormant Projects, H2 2015
Anthrax - Dormant Projects (Contd..1), H2 2015
Anthrax - Dormant Projects (Contd..2), H2 2015
Anthrax - Dormant Projects (Contd..3), H2 2015
Anthrax - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Anthrax, H2 2015
Number of Products under Development for Anthrax - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report